Drug Pricing Regulation ‘Would Best Serve Global Health’

Center for Global Development’s “Global Health Policy Blog”: The 5000% Price Increase and the Economic Case for Pharma Price Regulation
In light of a recent move by Turing Pharmaceuticals CEO Martin Shkreli to increase the price of the toxoplasmosis drug Daraprim by more than 5,000% overnight, CGD Senior Fellow Mead Over and Senior Policy Analyst Rachel Silverman discuss the global health implications of potential pharmaceutical pricing regulations. “…Just as utility companies best serve the public interest under government regulation for their local markets, multinational pharmaceutical companies would best serve global health under global regulation that supervises their international pricing as well as their research expenditures…” (9/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.